Key result
BNP assessment reliably aids HF diagnosis, prognosis, and treatment guidance in the community.
This review outlines the established and potential new roles for natriuretic peptide assessment in diagnosing, prognosticating, and managing heart failure in the community.
May support community HF management; leaves open prospective trials for treatment guidance.
Natriuretic peptide assessment has represented a significant advance in the management of heart failure. In a syndrome in which clinical symptoms and signs can be either nonspecific or absent, the presence of a reliable biomarker to aid diagnosis, assess prognosis, and potentially guide treatment and aid in prevention of this syndrome has represented a significant advance. The following review will outline established and potential new roles for natriuretic peptide assessment in the community. Congest Heart Fail. 2008;14(4 suppl 1):12–16.
No takes yet. Share an insight, caveat, or question.
McDonald et al. (2008) conducted a review in Heart failure. Natriuretic peptide assessment was evaluated. Natriuretic peptide assessment serves as a reliable biomarker to aid in the diagnosis, prognosis, and potential treatment guidance of heart failure in the community.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: